middle.news
Artrya Accelerates US Rollout with FDA Submission Imminent and $74M Cash Buffer
8:37am on Wednesday 29th of July, 2026 AEST
•
Healthcare
Read Story
Artrya Accelerates US Rollout with FDA Submission Imminent and $74M Cash Buffer
8:37am on Wednesday 29th of July, 2026 AEST
Key Points
Two US health systems generating revenue from Salix platform
FDA submission for Salix Coronary Flow module near completion
SAPPHIRE Study initiated to support clinical validation and adoption
Pro forma cash position of $74 million including term deposits
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Artrya (ASX:AYA)
OPEN ARTICLE